title: [Single instillation of epirubicin for the prophylaxis of recurrent primary superficial bladder carcinoma].
abstract: OBJECTIVE
  To determine the feasibility of single dose intravesical epirubicin in the prevention of recurrent superficial bladder carcinoma.
  
  
  METHODS
  We compared the effect of intravesical epirubicin or mitomycin C on tumor recurrence and disease free interval and their side effects after treatment of superficial bladder tumor. 47 postoperative patients with stages Ta to T1 primary superficial bladder carcinoma of grades 1 or 2 were randomized into groups A: single 80 mg epirubicin; B: 40 mg consecutive epirubicin; C: 40 mg consecutive mitomycin C. Patients were followed up for clinical, analytical, and cystoscopic evaluations every 3 months.
  
  
  RESULTS
  The disease free intervals of the three groups were found no significant differences (F = 3.25, P > 0.05). The recurrence rate was 6.25% (1/16), 13.3% (2/15), 12.5% (2/16) (chi(2) = 0.496, P > 0.05) in groups A, B, and C at 1 year, and 33.3% (5/15), 26.7% (4/15), 25% (4/16) (chi(2) = 0.290, P > 0.05) at 3 years after operation, respectively. Side effects of group A (13.3%) were lower than those of group B (46.7%) or C (43.8%) (chi(2) = 14.56, P < 0.01).
  
  
  CONCLUSIONS
  Single dose of epirubicin given intravesically immediately after tumor resection is effective in preventing tumor recurrence.
authors.affiliation: Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China.
authors.forename: Benchun
authors.initials: B
authors.lastname: Liu
authors.forename: Yuanfang
authors.initials: Y
authors.lastname: Zhang
authors.forename: Zhong
authors.initials: Z
authors.lastname: Wang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Ding
authors.forename: Bo
authors.initials: B
authors.lastname: Chen
authors.forename: Jigong
authors.initials: J
authors.lastname: Wang
authors.forename: Haowen
authors.initials: H
authors.lastname: Jiang
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*
chemical_list: D000903:Antibiotics, Antineoplastic; D015251:Epirubicin